首页 > 最新文献

Problemy endokrinologii最新文献

英文 中文
[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification]. [统一垂体神经内分泌肿瘤患者的病理形态学检查。新分类的争议问题]。
Pub Date : 2023-11-14 DOI: 10.14341/probl13376
V S Pronin, M B Antsiferov, T M Alekseeva, E V Pronin, A M Lapshina, L S Urusova

The progressive improvement of the classification using modern analytical methods is an essential tool for the development of precise and personalized approaches to the treatment of pituitary adenomas. In recent years, endocrinologists have witnessed evolutionary changes that have occurred in the histopathological identification of pituitary neoplasms, revealing new possibilities for studying tumorigenesis and predicting biological behavior.The paper considers the historical aspects of the gradual improvement of the classification of pituitary adenomas, as well as the new international 2022 WHO classification, according to which pituitary adenomas are included in the list of neuroendocrine tumors (PitNETs) to reflect the biological aggressiveness of some non-metastatic pituitary adenomas. The characteristics of pituitary adenoma are presented, as well as a list of histological subtypes of aggressive neuroendocrine tumors of the pituitary gland, marked by the main potentials for invasive growth, an increased risk of recurrence and a negative clinical prognosis.The expediency of changing the definition of «pituitary adenoma» to «neuroendocrine tumor» is discussed. It is emphasized that the introduction of a unified clinical, laboratory and morphological protocol into national clinical practice will help provide comparable comparative studies on the prognosis of the disease and the effectiveness of secondary therapy and also contribute to adequate management of potentially aggressive PitNETs.

利用现代分析方法逐步完善分类是开发精确和个性化垂体腺瘤治疗方法的重要工具。近年来,内分泌专家目睹了垂体肿瘤组织病理学鉴定方面发生的演变,揭示了研究肿瘤发生和预测生物学行为的新可能性。本文探讨了垂体腺瘤分类逐步完善的历史方面,以及2022年世卫组织的新国际分类,根据该分类,垂体腺瘤被列入神经内分泌肿瘤(PitNET)列表,以反映一些非转移性垂体腺瘤的生物学侵袭性。本文介绍了垂体腺瘤的特征,以及侵袭性垂体神经内分泌肿瘤的组织学亚型列表,这些亚型的主要特征是侵袭性生长、复发风险增加和临床预后不良。讨论了将 "垂体腺瘤 "的定义改为 "神经内分泌肿瘤 "的权宜之计,强调将统一的临床、实验室和形态学方案引入国家临床实践将有助于提供有关疾病预后和二次治疗效果的可比性比较研究,也有助于对潜在侵袭性垂体网状细胞瘤进行适当管理。
{"title":"[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification].","authors":"V S Pronin, M B Antsiferov, T M Alekseeva, E V Pronin, A M Lapshina, L S Urusova","doi":"10.14341/probl13376","DOIUrl":"10.14341/probl13376","url":null,"abstract":"<p><p>The progressive improvement of the classification using modern analytical methods is an essential tool for the development of precise and personalized approaches to the treatment of pituitary adenomas. In recent years, endocrinologists have witnessed evolutionary changes that have occurred in the histopathological identification of pituitary neoplasms, revealing new possibilities for studying tumorigenesis and predicting biological behavior.The paper considers the historical aspects of the gradual improvement of the classification of pituitary adenomas, as well as the new international 2022 WHO classification, according to which pituitary adenomas are included in the list of neuroendocrine tumors (PitNETs) to reflect the biological aggressiveness of some non-metastatic pituitary adenomas. The characteristics of pituitary adenoma are presented, as well as a list of histological subtypes of aggressive neuroendocrine tumors of the pituitary gland, marked by the main potentials for invasive growth, an increased risk of recurrence and a negative clinical prognosis.The expediency of changing the definition of «pituitary adenoma» to «neuroendocrine tumor» is discussed. It is emphasized that the introduction of a unified clinical, laboratory and morphological protocol into national clinical practice will help provide comparable comparative studies on the prognosis of the disease and the effectiveness of secondary therapy and also contribute to adequate management of potentially aggressive PitNETs.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 3","pages":"31-45"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Neuroendocrine features of the pathogenesis of polycystic ovary syndrome (literature review)]. 【多囊卵巢综合征发病机制的神经内分泌特征(文献综述)】。
Pub Date : 2023-11-12 DOI: 10.14341/probl13350
Yu S Absatarova, Yu S Evseeva, E N Andreeva

Polycystic ovary syndrome (PCOS) is one of the most pressing problems in endocrine gynecology. The main signs of the disease are hyperandrogenism, menstrual and/or ovulatory dysfunction, and polycystic ovarian structure according to ultrasound. Women with PCOS are at risk for developing metabolic syndrome, type 2 diabetes, cardiovascular disease, and endometrial cancer. In this connection, the pathogenetic mechanisms of the occurrence of this syndrome are continuously studied and new methods of treatment are being sought. PCOS is characterized by a wide range of various disorders of the neuroendocrine regulation of the reproductive system. The main focus of the review is aimed at summarizing information about the etiological role of neuropeptides and neurotransmitters, such as phoenixin, galanins, orexins, GABA, in the pathophysiology of PCOS and about the possibility of their use for diagnostic and therapeutic purposes. In recent decades, the interest of scientists has been focused on the study of KNDy neurons, because it is the kisspeptin synthesized by them that is one of the main regulators of the hypothalamic-pituitary-ovarian axis. This article discusses data on the significance of KNDy neurons in the pathogenesis of the syndrome. Information is provided on the effect of elevated levels of androgens and anti-Müllerian hormone on GnRH neurons. Also analyzed are studies on functional and structural disorders in the hypothalamus in PCOS. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The priority was free access to the full text of articles. The choice of sources was prioritized for the period from 2018 to 2023.However, taking into account the insufficient knowledge of the chosen topic, the choice of sources dates back to 1998.

多囊卵巢综合征(PCOS)是内分泌妇科领域亟待解决的问题之一。该病的主要征象为高雄激素,月经和/或排卵功能障碍,超声显示多囊卵巢结构。患有多囊卵巢综合征的女性有发生代谢综合征、2型糖尿病、心血管疾病和子宫内膜癌的风险。在这方面,不断研究该综合征发生的发病机制,并寻求新的治疗方法。多囊卵巢综合征的特点是广泛的各种生殖系统神经内分泌调节紊乱。本文主要综述了神经肽和神经递质(如凤凰素、甘丙氨酸、食欲素、GABA)在多囊卵巢综合征病理生理中的病因学作用及其在多囊卵巢综合征诊断和治疗中的应用。近几十年来,科学家们的兴趣一直集中在KNDy神经元的研究上,因为由它们合成的kisspeptin是下丘脑-垂体-卵巢轴的主要调节因子之一。本文讨论了KNDy神经元在该综合征发病机制中的意义。提供了关于雄激素和抗勒氏激素水平升高对GnRH神经元的影响的信息。并对多囊卵巢综合征下丘脑功能和结构紊乱的研究进行了分析。文献检索在国内(Library, CyberLeninka.ru)和国际(PubMed, Cochrane Library)数据库中进行了俄文和英文检索。优先事项是免费获取文章全文。在2018年至2023年期间,优先考虑资源的选择。然而,考虑到所选主题的知识不足,来源的选择可以追溯到1998年。
{"title":"[Neuroendocrine features of the pathogenesis of polycystic ovary syndrome (literature review)].","authors":"Yu S Absatarova, Yu S Evseeva, E N Andreeva","doi":"10.14341/probl13350","DOIUrl":"10.14341/probl13350","url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is one of the most pressing problems in endocrine gynecology. The main signs of the disease are hyperandrogenism, menstrual and/or ovulatory dysfunction, and polycystic ovarian structure according to ultrasound. Women with PCOS are at risk for developing metabolic syndrome, type 2 diabetes, cardiovascular disease, and endometrial cancer. In this connection, the pathogenetic mechanisms of the occurrence of this syndrome are continuously studied and new methods of treatment are being sought. PCOS is characterized by a wide range of various disorders of the neuroendocrine regulation of the reproductive system. The main focus of the review is aimed at summarizing information about the etiological role of neuropeptides and neurotransmitters, such as phoenixin, galanins, orexins, GABA, in the pathophysiology of PCOS and about the possibility of their use for diagnostic and therapeutic purposes. In recent decades, the interest of scientists has been focused on the study of KNDy neurons, because it is the kisspeptin synthesized by them that is one of the main regulators of the hypothalamic-pituitary-ovarian axis. This article discusses data on the significance of KNDy neurons in the pathogenesis of the syndrome. Information is provided on the effect of elevated levels of androgens and anti-Müllerian hormone on GnRH neurons. Also analyzed are studies on functional and structural disorders in the hypothalamus in PCOS. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The priority was free access to the full text of articles. The choice of sources was prioritized for the period from 2018 to 2023.However, taking into account the insufficient knowledge of the chosen topic, the choice of sources dates back to 1998.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"107-114"},"PeriodicalIF":0.0,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hormonal and genetic causes of cryptorchidism]. [隐睾的激素和遗传原因]。
Pub Date : 2023-11-12 DOI: 10.14341/probl13242
E M Oreshkina, N V Bolotova, T E Pylaev, A P Averyanov, N Y Raygorodskaya

Cryptorchidism is the most frequent congenital disorders of the reproductive system, is present in 2-3% of term newborn boys. Genes involved in embryonic testicular migration are known but their role in cryptorchidism development are not investigated enough. Genetical causes of cryptorchidism are identified in 5-7% of patients. The article contains data on the role of insulin-like peptide 3 and its receptor, anti-Müllerian hormone, gonadotropins, androgens in embryonic testicular migration. INSL3 and AMH are presented as markers of testicular dysfunction associated with cryptorchidism. Hypogonadotropic hypogonadism is also associated with cryptorchidism and can be diagnosed based on it. Results of modern investigations determine the necessary of hormonal and genetical examination of patients with isolated cryptorchidism to detect causes of cryptorchidism and manage of patients.

隐睾是生殖系统最常见的先天性疾病,在足月新生儿中占2-3%。参与胚胎睾丸迁移的基因是已知的,但它们在隐睾发育中的作用尚未得到足够的研究。在5-7%的患者中发现了隐睾症的遗传原因。本文介绍了胰岛素样肽3及其受体、抗勒氏激素、促性腺激素、雄激素在胚胎睾丸迁移中的作用。INSL3和AMH被认为是与隐睾相关的睾丸功能障碍的标志。促性腺功能减退症也与隐睾有关,可据此诊断。现代调查结果确定了孤立性隐睾患者进行激素和遗传检查的必要性,以发现隐睾的原因和患者的管理。
{"title":"[Hormonal and genetic causes of cryptorchidism].","authors":"E M Oreshkina, N V Bolotova, T E Pylaev, A P Averyanov, N Y Raygorodskaya","doi":"10.14341/probl13242","DOIUrl":"10.14341/probl13242","url":null,"abstract":"<p><p>Cryptorchidism is the most frequent congenital disorders of the reproductive system, is present in 2-3% of term newborn boys. Genes involved in embryonic testicular migration are known but their role in cryptorchidism development are not investigated enough. Genetical causes of cryptorchidism are identified in 5-7% of patients. The article contains data on the role of insulin-like peptide 3 and its receptor, anti-Müllerian hormone, gonadotropins, androgens in embryonic testicular migration. INSL3 and AMH are presented as markers of testicular dysfunction associated with cryptorchidism. Hypogonadotropic hypogonadism is also associated with cryptorchidism and can be diagnosed based on it. Results of modern investigations determine the necessary of hormonal and genetical examination of patients with isolated cryptorchidism to detect causes of cryptorchidism and manage of patients.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"99-106"},"PeriodicalIF":0.0,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia]. [俄罗斯规定绝经期激素治疗心血管和代谢疾病患者的资格标准。俄罗斯心脏病学会,俄罗斯妇产科医师学会,俄罗斯内分泌学家协会,欧亚治疗师协会,俄罗斯静脉学家协会的共识文件]。
Pub Date : 2023-11-12 DOI: 10.14341/probl13394
E V Shlyakhto, G T Sukhikh, V N Serov, I I Dedov, G P Arutyunov, I A Suchkov, Ya A Orlova, E N Andreeva, S V Yureneva, I S Yavelov, M I Yarmolinskaya, S V Villevalde, O R Grigoryan, E N Dudinskaya, E A Ilyukhin, N A Koziolova, I V Sergienko, A A Smetnik, N I Tapilskaya

Menopausal symptoms can disrupt the life course of women at the peak of their career and family life. Currently, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormonal therapy is the fear of doctors who are afraid of doing more harm to patients than good. Caution is especially important when it comes to women with underlying health conditions. Moreover, it should be recognized that there is a lack of high-quality research regarding the safety of MHT for major chronic non-infectious diseases and common comorbid conditions. The presented consensus document analyzed all currently available data obtained from clinical trials of various designs and created a set of criteria for the acceptability of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, doctors of various specialties who advise women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real practice.

更年期症状会扰乱女性在事业和家庭生活高峰期的生活进程。目前,治疗这些症状最有效的方法是绝经期激素治疗(MHT)。心血管和代谢疾病本身的存在并不排除处方MHT来缓解更年期症状和改善生活质量的可能性。然而,使用这种激素疗法的一个障碍往往是医生的恐惧,他们害怕对病人的伤害大于好处。当涉及到有潜在健康问题的女性时,谨慎尤为重要。此外,应该认识到,关于MHT治疗主要慢性非传染性疾病和常见合并症的安全性缺乏高质量的研究。提出的共识文件分析了目前从各种设计的临床试验中获得的所有可用数据,并制定了一套标准,以确定对患有合并心血管和代谢疾病的妇女开MHT的可接受性。基于所呈现的文件,为更年期妇女提供建议的不同专业的医生将获得一个可访问的算法,这将使他们能够避免潜在的危险情况,并在实际操作中合理地开出MHT。
{"title":"[Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia].","authors":"E V Shlyakhto, G T Sukhikh, V N Serov, I I Dedov, G P Arutyunov, I A Suchkov, Ya A Orlova, E N Andreeva, S V Yureneva, I S Yavelov, M I Yarmolinskaya, S V Villevalde, O R Grigoryan, E N Dudinskaya, E A Ilyukhin, N A Koziolova, I V Sergienko, A A Smetnik, N I Tapilskaya","doi":"10.14341/probl13394","DOIUrl":"10.14341/probl13394","url":null,"abstract":"<p><p>Menopausal symptoms can disrupt the life course of women at the peak of their career and family life. Currently, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormonal therapy is the fear of doctors who are afraid of doing more harm to patients than good. Caution is especially important when it comes to women with underlying health conditions. Moreover, it should be recognized that there is a lack of high-quality research regarding the safety of MHT for major chronic non-infectious diseases and common comorbid conditions. The presented consensus document analyzed all currently available data obtained from clinical trials of various designs and created a set of criteria for the acceptability of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, doctors of various specialties who advise women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real practice.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"115-136"},"PeriodicalIF":0.0,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Association between treatment outcome and age in tuberculosis and diabetes patients: a population analysis]. [结核病和糖尿病患者治疗结果与年龄的关系:一项人群分析]。
Pub Date : 2023-11-12 DOI: 10.14341/probl13252
L T Yeraliyeva, A M Issayeva

Background: The undoubted importance of this work lies in the fact that for the first time in the Republic of Kazakhstan, an analysis is being made of the relationship between age and treatment outcome in patients with a comorbid diagnosis of tuberculosis and diabetes mellitus.

Purpose of the study: Identification of the correlation between the age of patients with tuberculosis with diabetes mellitus and the outcome of treatment.

Materials and methods: Cross-sectional retrospective study of 2,125 patients with TB and diabetes mellitus out of a total of 43,807 of all patients diagnosed with TB (2017-2019). The study analyzed the data of patients with comorbidity from all regions of Kazakhstan (data from 14 regions and 3 cities of republican significance) (2017-2019).

Results: A high prevalence of tuberculosis morbidity with a concomitant diagnosis of diabetes mellitus in the age group from 45 to 64 years was revealed. This group consisted of 1193 patients out of 2115 (56.4% of the total number of patients with tuberculosis and diabetes mellitus). The average age of all studied patients with DM was 54.7±13.4 years. There is a positive correlation between age and treatment outcome in TB patients. Mortality was higher in the age group over 45 years old - OR95%CI = 0.213 [0.019-2.362], p - 0.0000015 (p < 0.05).

背景:毫无疑问,这项工作的重要性在于,哈萨克斯坦共和国首次对合并诊断为肺结核和糖尿病的患者的年龄与治疗结果之间的关系进行了分析。研究目的:探讨结核合并糖尿病患者年龄与治疗效果的相关性。材料与方法:2017-2019年,在43,807例结核病患者中,对2,125例结核病合并糖尿病患者进行横断面回顾性研究。本研究分析了哈萨克斯坦所有地区共病患者的数据(来自14个地区和3个共和意义城市的数据)(2017-2019年)。结果:在45 ~ 64岁年龄组中,肺结核发病率高,并伴有糖尿病。该组包括2115例患者中的1193例(占结核合并糖尿病患者总数的56.4%)。所有DM患者的平均年龄为54.7±13.4岁。结核病患者的年龄与治疗结果呈正相关。45岁以上年龄组死亡率较高,OR95%CI = 0.213 [0.019-2.362], p - 0.0000015 (p <0.05)。
{"title":"[Association between treatment outcome and age in tuberculosis and diabetes patients: a population analysis].","authors":"L T Yeraliyeva, A M Issayeva","doi":"10.14341/probl13252","DOIUrl":"10.14341/probl13252","url":null,"abstract":"<p><strong>Background: </strong>The undoubted importance of this work lies in the fact that for the first time in the Republic of Kazakhstan, an analysis is being made of the relationship between age and treatment outcome in patients with a comorbid diagnosis of tuberculosis and diabetes mellitus.</p><p><strong>Purpose of the study: </strong>Identification of the correlation between the age of patients with tuberculosis with diabetes mellitus and the outcome of treatment.</p><p><strong>Materials and methods: </strong>Cross-sectional retrospective study of 2,125 patients with TB and diabetes mellitus out of a total of 43,807 of all patients diagnosed with TB (2017-2019). The study analyzed the data of patients with comorbidity from all regions of Kazakhstan (data from 14 regions and 3 cities of republican significance) (2017-2019).</p><p><strong>Results: </strong>A high prevalence of tuberculosis morbidity with a concomitant diagnosis of diabetes mellitus in the age group from 45 to 64 years was revealed. This group consisted of 1193 patients out of 2115 (56.4% of the total number of patients with tuberculosis and diabetes mellitus). The average age of all studied patients with DM was 54.7±13.4 years. There is a positive correlation between age and treatment outcome in TB patients. Mortality was higher in the age group over 45 years old - OR95%CI = 0.213 [0.019-2.362], p - 0.0000015 (p &lt; 0.05).</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Corticotropin-producing pheochromocytoma in multiple endocrine neoplasia type 1]. [1型多发性内分泌瘤中促肾上腺皮质激素生成嗜铬细胞瘤]。
Pub Date : 2023-11-11 DOI: 10.14341/probl13260
D V Rebrova, S I Grigorova, N V Vorokhobina, E A Zgoda, K Yu Novokshonov, S G Feofanova, V F Rusakov, L M Krasnov, E A Fedorov, I K Chinchuk, Sh Sh Shikhmagomedov, A A Pushkaruk, I V Sleptsov

A clinical case of a man 66 y.o. who was diagnosed with hormone-inactive pituitary macroadenoma complicated by corneal erosion and partial atrophy of the optic nerve of the left eye due to exophthalmos. The increase in prolactin level was regarded due to a «stalk-effect». The patient underwent a transnasal pituitary adenomectomy with subsequent regression of symptoms. After 4 years, against the background of a new coronavirus infection, increasing general weakness, headaches, a crisis increase in blood pressure and tachycardia attacks appeared. Computed tomography (CT) accidentally revealed an adrenal incidentaloma, in laboratory tests - hypercortisolism, elevated ACTH levels, hypokalemia, hyperglycemia, increased levels of metanephrine and normetanephrine. The patient developed acute steroid psychosis, after which an adrenalectomy with a tumor was performed, a pheochromocytoma was histologically confirmed. After surgery, there was a regression of symptoms, the development of adrenal insufficiency with reduced levels of ACTH and cortisol. Upon further examination, a polynodose euthyroid goiter was established, the biopsy of the nodes - Hashimoto's thyroiditis (Bethesda II). Meanwhile, primary hyperparathyroidism was detected. According to ultrasound, scintigraphy with Ts99m-Technetril and CT revealed an increase of left parathyroid gland. A bilateral revision of the neck, removal of the right upper and left upper parathyroid adenomas were performed. In the postoperative period, the levels of calcium and parathyroid hormone were normalized. Given the presence of a combination of multiple tumors of the endocrine system (primary hyperparathyroidism, corticotropin-producing pheochromocytoma, hormone-inactive pituitary macroadenoma, polynodose euthyroid goiter), the MEN1 syndrome was clinically established. The study of 2 and 10 exons of the MEN1 gene revealed no mutations, which does not exclude the presence of a hereditary syndrome. The patient continues observation. In the available literature in Russian and English languages the case of ACTH pheochromocytoma as part of the MEN type 1 syndrome have not been found. Therefore, we consider the presented case to be the first one.

一位66岁的男性被诊断为激素无活性垂体大腺瘤并发角膜侵蚀和左眼视神经部分萎缩的临床病例。催乳素水平的增加被认为是由于“茎效应”。患者接受经鼻垂体腺瘤切除术,随后症状消退。4年后,在一种新的冠状病毒感染的背景下,全身虚弱、头痛、血压危重性升高和心动过速发作出现了。计算机断层扫描(CT)在实验室检查中意外发现肾上腺偶发瘤-高皮质醇,ACTH水平升高,低钾血症,高血糖,肾上腺素和去甲肾上腺素水平升高。患者发展为急性类固醇性精神病,在肾上腺切除并行肿瘤后,病理证实为嗜铬细胞瘤。手术后,症状消退,发展为肾上腺功能不全,ACTH和皮质醇水平降低。经进一步检查,发现多结节性甲状腺肿大,淋巴结活检-桥本甲状腺炎(Bethesda II)。同时,发现原发性甲状旁腺功能亢进。超声、ts99m显像及CT示左侧甲状旁腺增高。双侧颈部翻修,切除右上、左上甲状旁腺瘤。术后钙、甲状旁腺激素水平恢复正常。考虑到内分泌系统多发肿瘤(原发性甲状旁腺功能亢进、促肾上腺皮质激素分泌嗜铬细胞瘤、激素无活性垂体大腺瘤、多结节性甲状腺良性甲状腺肿)的合并存在,MEN1综合征在临床上被确立。对MEN1基因2和10个外显子的研究显示没有突变,这并不排除遗传综合征的存在。病人继续观察。在俄语和英语的现有文献中,ACTH嗜铬细胞瘤作为MEN 1型综合征的一部分尚未发现。因此,我们认为所提出的情况是第一个。
{"title":"[Corticotropin-producing pheochromocytoma in multiple endocrine neoplasia type 1].","authors":"D V Rebrova, S I Grigorova, N V Vorokhobina, E A Zgoda, K Yu Novokshonov, S G Feofanova, V F Rusakov, L M Krasnov, E A Fedorov, I K Chinchuk, Sh Sh Shikhmagomedov, A A Pushkaruk, I V Sleptsov","doi":"10.14341/probl13260","DOIUrl":"10.14341/probl13260","url":null,"abstract":"<p><p>A clinical case of a man 66 y.o. who was diagnosed with hormone-inactive pituitary macroadenoma complicated by corneal erosion and partial atrophy of the optic nerve of the left eye due to exophthalmos. The increase in prolactin level was regarded due to a «stalk-effect». The patient underwent a transnasal pituitary adenomectomy with subsequent regression of symptoms. After 4 years, against the background of a new coronavirus infection, increasing general weakness, headaches, a crisis increase in blood pressure and tachycardia attacks appeared. Computed tomography (CT) accidentally revealed an adrenal incidentaloma, in laboratory tests - hypercortisolism, elevated ACTH levels, hypokalemia, hyperglycemia, increased levels of metanephrine and normetanephrine. The patient developed acute steroid psychosis, after which an adrenalectomy with a tumor was performed, a pheochromocytoma was histologically confirmed. After surgery, there was a regression of symptoms, the development of adrenal insufficiency with reduced levels of ACTH and cortisol. Upon further examination, a polynodose euthyroid goiter was established, the biopsy of the nodes - Hashimoto's thyroiditis (Bethesda II). Meanwhile, primary hyperparathyroidism was detected. According to ultrasound, scintigraphy with Ts99m-Technetril and CT revealed an increase of left parathyroid gland. A bilateral revision of the neck, removal of the right upper and left upper parathyroid adenomas were performed. In the postoperative period, the levels of calcium and parathyroid hormone were normalized. Given the presence of a combination of multiple tumors of the endocrine system (primary hyperparathyroidism, corticotropin-producing pheochromocytoma, hormone-inactive pituitary macroadenoma, polynodose euthyroid goiter), the MEN1 syndrome was clinically established. The study of 2 and 10 exons of the MEN1 gene revealed no mutations, which does not exclude the presence of a hereditary syndrome. The patient continues observation. In the available literature in Russian and English languages the case of ACTH pheochromocytoma as part of the MEN type 1 syndrome have not been found. Therefore, we consider the presented case to be the first one.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"55-64"},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review]. [降糖药物在阿尔茨海默病治疗中的作用:系统综述]。
Pub Date : 2023-11-11 DOI: 10.14341/probl13183
A N Ishmuratova, M A Abramov, K O Kuznetsov, M V Ivanyuta, Z F Shakirova, A I Kitapova, M D Usmonov, L M Chernousova, L I Valeeva, A Yu Kuznetsova, A S Baislamov, A R Shaihetdinova, A A Mirgaliev, S T Orozberdiev, K I Yakupova

Recent studies show that Alzheimer's disease (AD) has many common links with conditions associated with insulin resistance, including neuroinflammation, impaired insulin signaling, oxidative stress, mitochondrial dysfunction and metabolic syndrome. The authors conducted an electronic search for publications in the PubMed/MEDLINE and Google Scholar databases using the keywords "amyloid beta", "Alzheimer type-3-diabetes", "intranasal insulin", "metformin", "type 2 diabetes mellitus", "incretins" and "PPARy agonists». A systematic literature search was conducted among studies published between 2005 and 2022. The authors used the following inclusion criteria: 1) Subjects who received therapy for AD and/or DM2, if the expected result concerned the risk of cognitive decline or the development of dementia; 2) The age of the study participants is > 50 years; 3) The type of studies included in this review were randomized clinical trials, population-based observational studies or case-control studies, prospective cohort studies, as well as reviews and meta-analyses; 4) The included articles were written in English. In recent years, there has been considerable interest in identifying the mechanisms of action of antidiabetic drugs and their potential use in AD. Human studies involving patients with mild cognitive impairment and Alzheimer's disease have shown that the administration of certain antidiabetic drugs, such as intranasal insulin, metformin, incretins and thiazolidinediones, can improve cognitive function and memory. The purpose of this study is to evaluate the effectiveness of antidiabetic drugs in the treatment of AD. According to the results of the study, metformin, intranasal insulin, thiazolidinediones and incretins showed a positive effect both in humans and in animal models. Recent studies show that thiazolidinediones can activate pathways in the brain that are regulated by IGF-1; however, rosiglitazone may pose a significant risk of side effects. The results of clinical studies on the use of metformin in AD are limited and contradictory.

最近的研究表明,阿尔茨海默病(AD)与胰岛素抵抗相关的疾病有许多共同的联系,包括神经炎症、胰岛素信号受损、氧化应激、线粒体功能障碍和代谢综合征。作者在PubMed/MEDLINE和谷歌Scholar数据库中使用关键词“淀粉样蛋白”、“阿尔茨海默3型糖尿病”、“鼻内胰岛素”、“二甲双胍”、“2型糖尿病”、“肠促胰岛素”和“pparty激动剂”对出版物进行了电子搜索。对2005年至2022年间发表的研究进行了系统的文献检索。作者采用以下纳入标准:1)接受AD和/或DM2治疗的受试者,如果预期结果涉及认知能力下降或痴呆发展的风险;2)研究参与者年龄为>50年;3)本综述纳入的研究类型为随机临床试验、基于人群的观察性研究或病例对照研究、前瞻性队列研究以及综述和荟萃分析;4)收录的文章均为英文。近年来,人们对确定抗糖尿病药物的作用机制及其在AD中的潜在应用产生了相当大的兴趣。对患有轻度认知障碍和阿尔茨海默病的患者进行的人体研究表明,某些抗糖尿病药物,如鼻内胰岛素、二甲双胍、肠促胰岛素和噻唑烷二酮类药物,可以改善认知功能和记忆。本研究的目的是评价抗糖尿病药物治疗AD的有效性。根据研究结果,二甲双胍、鼻内胰岛素、噻唑烷二酮类药物和肠促胰岛素在人类和动物模型中都显示出积极的效果。最近的研究表明,噻唑烷二酮可以激活大脑中受IGF-1调节的通路;然而,罗格列酮可能有显著的副作用风险。二甲双胍治疗AD的临床研究结果有限且相互矛盾。
{"title":"[The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].","authors":"A N Ishmuratova, M A Abramov, K O Kuznetsov, M V Ivanyuta, Z F Shakirova, A I Kitapova, M D Usmonov, L M Chernousova, L I Valeeva, A Yu Kuznetsova, A S Baislamov, A R Shaihetdinova, A A Mirgaliev, S T Orozberdiev, K I Yakupova","doi":"10.14341/probl13183","DOIUrl":"10.14341/probl13183","url":null,"abstract":"<p><p>Recent studies show that Alzheimer's disease (AD) has many common links with conditions associated with insulin resistance, including neuroinflammation, impaired insulin signaling, oxidative stress, mitochondrial dysfunction and metabolic syndrome. The authors conducted an electronic search for publications in the PubMed/MEDLINE and Google Scholar databases using the keywords \"amyloid beta\", \"Alzheimer type-3-diabetes\", \"intranasal insulin\", \"metformin\", \"type 2 diabetes mellitus\", \"incretins\" and \"PPARy agonists». A systematic literature search was conducted among studies published between 2005 and 2022. The authors used the following inclusion criteria: 1) Subjects who received therapy for AD and/or DM2, if the expected result concerned the risk of cognitive decline or the development of dementia; 2) The age of the study participants is &gt; 50 years; 3) The type of studies included in this review were randomized clinical trials, population-based observational studies or case-control studies, prospective cohort studies, as well as reviews and meta-analyses; 4) The included articles were written in English. In recent years, there has been considerable interest in identifying the mechanisms of action of antidiabetic drugs and their potential use in AD. Human studies involving patients with mild cognitive impairment and Alzheimer's disease have shown that the administration of certain antidiabetic drugs, such as intranasal insulin, metformin, incretins and thiazolidinediones, can improve cognitive function and memory. The purpose of this study is to evaluate the effectiveness of antidiabetic drugs in the treatment of AD. According to the results of the study, metformin, intranasal insulin, thiazolidinediones and incretins showed a positive effect both in humans and in animal models. Recent studies show that thiazolidinediones can activate pathways in the brain that are regulated by IGF-1; however, rosiglitazone may pose a significant risk of side effects. The results of clinical studies on the use of metformin in AD are limited and contradictory.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"73-83"},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical features and complication rates in type 2 diabetes mellitus clusters on five variables: glycated hemoglobin, age at diagnosis, body mass index, HOMA-IR, HOMA-B]. [2型糖尿病的临床特征及并发症发生率在糖化血红蛋白、诊断年龄、体重指数、HOMA-IR、HOMA-B 5个变量上聚集]。
Pub Date : 2023-11-11 DOI: 10.14341/probl13259
I A Bondar, O Y Shabelnikova

Background: Diabetes mellitus (T2DM) is a serious medical and social problem. Now they are studying the possibility of a new stratification of diabetes. The possibility of cluster analysis for different durations of diabetes, in different cohorts to identify phenotypic clusters of T2DM and validation by reproducing clusters is relevant.

Aim: Identify clusters of type 2 diabetes mellitus in patients with different disease duration based on five variables: HbA1c, age at diagnosis, BMI, HOMA-IR, HOMA-B and study the clinical features and complication rates in each cluster in the Novosibirsk region.

Materials and methods: Cluster analysis of K-means was performed in 2131 patients with T2DM, aged 44 to 70 years, with a duration of diabetes of 6.42±5.66 years, living in the Novosibirsk region based on 5 variables - HbA1c, age at -diagnosis, BMI, HOMA-IR, HOMA-B. All patients a complete clinical and laboratory examination. The insulin resistance index in the HOMA (HOMA-IR, u) and the β-cell function assessment index (HOMA-B) were calculated using the calculator -version 2.2.3 at www.dtu.ox.ac.uk.

Results: Cluster analysis revealed: Cluster 1 included 455 patients with preserved β-cell function (HOMA-B 82.97±23.28%), moderate insulin resistance (HOMA-IR 5.57±4.72) and higher diastolic BP; Cluster 2 in 1658 patients with reduced function of β-cells (HOMA-B 21.71±12.51%), the lowest indices of insulin resistance (HOMA-IR 3.50±2.48) and was characterized by a longer duration of diabetes, high fasting glycemia , HbA1c, higher eGFR and MAU, men compared with women had a 31% higher risk of developing diabetic neuropathy and 28% more diabetic nephropathy; Cluster 3 in 18 patients with high function of β-cells (HOMA-B 228.53±63.32%), severe insulin resistance (HOMA-IR 6.92±4.77), features were high incidence of men, shorter duration of diabetes, lower fasting glycemia and HbA1c, lower diastolic BP and eGFR, high incidence of early development of diabetic retinopathy after 4.00±3.6 years.

Conclusion: Cluster analysis in patients with different durations of diabetes mellitus confirmed the possibility of using cluster analysis to identify T2DM phenotypes in the Russian population. The clusters differed in the clinical characteristics of patients, the frequency and risk of diabetic complications. These results have potential value for early stratification of therapy.

背景:糖尿病(T2DM)是一个严重的医学和社会问题。现在他们正在研究一种新的糖尿病分层的可能性。在不同的队列中,对不同病程的糖尿病进行聚类分析,以确定T2DM的表型聚类,并通过重复聚类进行验证的可能性是相关的。目的:根据HbA1c、诊断年龄、BMI、HOMA-IR、HOMA-B 5个变量,识别不同病程的2型糖尿病患者的聚类,研究新西伯利亚地区各聚类的临床特征及并发症发生率。材料与方法:以HbA1c、诊断年龄、BMI、HOMA-IR、HOMA-B 5个变量为基础,对生活在新西伯利亚地区的2131例年龄44 ~ 70岁、糖尿病病程6.42±5.66年的T2DM患者进行K-means聚类分析。所有患者均进行了完整的临床和实验室检查。采用2.2.3版计算器(www.dtu.ox.ac.uk.Results)计算HOMA胰岛素抵抗指数(HOMA- ir, u)和β细胞功能评估指数(HOMA- b)。聚类分析显示:聚类1包括455例β细胞功能保持(HOMA- b为82.97±23.28%)、中度胰岛素抵抗(HOMA- ir为5.57±4.72)、舒张压较高的患者;第2组1658例β-细胞功能降低(HOMA-B 21.71±12.51%),胰岛素抵抗指数最低(HOMA-IR 3.50±2.48),糖尿病持续时间更长,空腹血糖、HbA1c较高,eGFR和MAU较高,男性发生糖尿病神经病变的风险比女性高31%,糖尿病肾病的风险比女性高28%;第3组18例β-细胞功能高(HOMA-B 228.53±63.32%),胰岛素抵抗严重(HOMA-IR 6.92±4.77),特征为男性发病率高,糖尿病持续时间短,空腹血糖和HbA1c较低,舒张压和eGFR较低,4.00±3.6年后早期发展为糖尿病视网膜病变的发病率高。结论:对不同病程的糖尿病患者进行聚类分析,证实了利用聚类分析识别俄罗斯人群中T2DM表型的可能性。这些集群在患者的临床特征、糖尿病并发症的频率和风险方面存在差异。这些结果对早期分层治疗具有潜在的价值。
{"title":"[Clinical features and complication rates in type 2 diabetes mellitus clusters on five variables: glycated hemoglobin, age at diagnosis, body mass index, HOMA-IR, HOMA-B].","authors":"I A Bondar, O Y Shabelnikova","doi":"10.14341/probl13259","DOIUrl":"10.14341/probl13259","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus (T2DM) is a serious medical and social problem. Now they are studying the possibility of a new stratification of diabetes. The possibility of cluster analysis for different durations of diabetes, in different cohorts to identify phenotypic clusters of T2DM and validation by reproducing clusters is relevant.</p><p><strong>Aim: </strong>Identify clusters of type 2 diabetes mellitus in patients with different disease duration based on five variables: HbA1c, age at diagnosis, BMI, HOMA-IR, HOMA-B and study the clinical features and complication rates in each cluster in the Novosibirsk region.</p><p><strong>Materials and methods: </strong>Cluster analysis of K-means was performed in 2131 patients with T2DM, aged 44 to 70 years, with a duration of diabetes of 6.42±5.66 years, living in the Novosibirsk region based on 5 variables - HbA1c, age at -diagnosis, BMI, HOMA-IR, HOMA-B. All patients a complete clinical and laboratory examination. The insulin resistance index in the HOMA (HOMA-IR, u) and the β-cell function assessment index (HOMA-B) were calculated using the calculator -version 2.2.3 at www.dtu.ox.ac.uk.</p><p><strong>Results: </strong>Cluster analysis revealed: Cluster 1 included 455 patients with preserved β-cell function (HOMA-B 82.97±23.28%), moderate insulin resistance (HOMA-IR 5.57±4.72) and higher diastolic BP; Cluster 2 in 1658 patients with reduced function of β-cells (HOMA-B 21.71±12.51%), the lowest indices of insulin resistance (HOMA-IR 3.50±2.48) and was characterized by a longer duration of diabetes, high fasting glycemia , HbA1c, higher eGFR and MAU, men compared with women had a 31% higher risk of developing diabetic neuropathy and 28% more diabetic nephropathy; Cluster 3 in 18 patients with high function of β-cells (HOMA-B 228.53±63.32%), severe insulin resistance (HOMA-IR 6.92±4.77), features were high incidence of men, shorter duration of diabetes, lower fasting glycemia and HbA1c, lower diastolic BP and eGFR, high incidence of early development of diabetic retinopathy after 4.00±3.6 years.</p><p><strong>Conclusion: </strong>Cluster analysis in patients with different durations of diabetes mellitus confirmed the possibility of using cluster analysis to identify T2DM phenotypes in the Russian population. The clusters differed in the clinical characteristics of patients, the frequency and risk of diabetic complications. These results have potential value for early stratification of therapy.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"84-92"},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Reset osmostat syndrome - when hyponatremia become «a normal»: diagnostics, case report]. [重置渗透综合征-当低钠血症成为“正常”:诊断,病例报告]。
Pub Date : 2023-11-11 DOI: 10.14341/probl13235
L I Astafyeva, I N Badmaeva, I S Klochkova, Yu G Sidneva, O I Sharipov, O A Gadjieva, B A Bashiryan, P L Kalinin, A Yu Lubnin, A N Konovalov

Reset osmostat syndrome (ROS) is characterized by a change of normal plasma osmolality threshold (decrease or increase), which leads to chronic dysnatremia (hypo- or hypernatremia). We have described a clinical case of ROS and chronic hyponatremia in a patient with chordoid glioma of the III ventricle. It is known that the patient had previously been diagnosed with hyponatremia (131-134 mmol/l). She has not hypothyroidism and hypocorticism. There is normal filtration function of the kidneys was (CKD-EPI 91.7 ml/mi/1,73m2). Urine osmolality and sodium level were studied to exclude of concentration kidney function disorder. During first three days after removal of the tumor of the third ventricle (chordoid glioma, WHO Grade II), the sodium level decreased to 119 mmol/l. Repeated infusions of 200-300 ml hypertonic 3% sodium chloride solution, gluco- and mineralocorticoid therapy was ineffective, increasing plasma sodium levels by 2-3 mmol/l with the return to the initial level during 6-8 hours. Hypopituitary disorders did not develop after surgery. With further observation, the sodium level remained within 126-129 mmol/l for 6 months after surgery. The water load test make exclude the classic syndrome of inappropriate secretion of antidiuretic hormone, and confirmed the diagnosis of RSO. Because of absence of clinical symptoms associated with hyponatremia, no medical correction was required, patient was recommended to clinical follow-up.

重置渗透压综合征(ROS)的特征是正常血浆渗透压阈值的改变(降低或增加),从而导致慢性钠血症(低钠血症或高钠血症)。我们已经描述了一个临床病例ROS和慢性低钠血症患者脊索样胶质瘤的第三脑室。已知患者先前被诊断为低钠血症(131-134 mmol/l)。她没有甲状腺功能减退和虚荣症。肾脏滤过功能正常(CKD-EPI 91.7 ml/mi/1,73m2)。研究尿渗透压和钠水平以排除浓缩性肾功能障碍。在切除第三脑室肿瘤(脊索样胶质瘤,WHO II级)后的头三天,钠水平降至119 mmol/l。反复输注高渗3%氯化钠溶液200 ~ 300 ml,糖皮质激素和糖皮质激素治疗无效,可使血浆钠水平升高2 ~ 3 mmol/l, 6 ~ 8 h后恢复到初始水平。术后未发生垂体功能障碍。进一步观察,术后6个月钠水平维持在126-129 mmol/l。水负荷试验排除了典型的抗利尿激素分泌异常综合征,证实了RSO的诊断。由于无与低钠血症相关的临床症状,不需要医学纠正,建议患者进行临床随访。
{"title":"[Reset osmostat syndrome - when hyponatremia become «a normal»: diagnostics, case report].","authors":"L I Astafyeva, I N Badmaeva, I S Klochkova, Yu G Sidneva, O I Sharipov, O A Gadjieva, B A Bashiryan, P L Kalinin, A Yu Lubnin, A N Konovalov","doi":"10.14341/probl13235","DOIUrl":"10.14341/probl13235","url":null,"abstract":"<p><p>Reset osmostat syndrome (ROS) is characterized by a change of normal plasma osmolality threshold (decrease or increase), which leads to chronic dysnatremia (hypo- or hypernatremia). We have described a clinical case of ROS and chronic hyponatremia in a patient with chordoid glioma of the III ventricle. It is known that the patient had previously been diagnosed with hyponatremia (131-134 mmol/l). She has not hypothyroidism and hypocorticism. There is normal filtration function of the kidneys was (CKD-EPI 91.7 ml/mi/1,73m2). Urine osmolality and sodium level were studied to exclude of concentration kidney function disorder. During first three days after removal of the tumor of the third ventricle (chordoid glioma, WHO Grade II), the sodium level decreased to 119 mmol/l. Repeated infusions of 200-300 ml hypertonic 3% sodium chloride solution, gluco- and mineralocorticoid therapy was ineffective, increasing plasma sodium levels by 2-3 mmol/l with the return to the initial level during 6-8 hours. Hypopituitary disorders did not develop after surgery. With further observation, the sodium level remained within 126-129 mmol/l for 6 months after surgery. The water load test make exclude the classic syndrome of inappropriate secretion of antidiuretic hormone, and confirmed the diagnosis of RSO. Because of absence of clinical symptoms associated with hyponatremia, no medical correction was required, patient was recommended to clinical follow-up.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"65-72"},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Surgical treatment of pheochromocytoma]. 嗜铬细胞瘤的外科治疗。
Pub Date : 2023-11-11 DOI: 10.14341/probl13283
Sh Sh Shikhmagomedov, D V Rebrova, L M Krasnov, E A Fedorov, I K Chinchuk, R A Chernikov, V F Rusakov, I V Slepstov, E A Zgoda

This review article contains a summary of modern aspects of preoperative preparation, surgical treatment, and follow-up of patients with adrenal pheochromocytomas. The main component of preoperative preparation is the use of alpha-blockers. The need to prescribe them to all patients is increasingly disputed, especially for patients without severe hypertension. An increasing number of publications demonstrate positive results of treatment without the use of alpha-blockers, advocating an individual approach and the use of the drug according to certain indications. Minimally invasive endoscopic techniques of adrenalectomy have become widespread in surgical treatment. They are represented by laparoscopic and retroperitonescopic technic, including using their single-port modifications. The earliest possible intersection of the central vein in the past was considered the most important aspect of adrenalectomy for pheochromocytoma, currently, due to the development of surgical techniques and anesthesiological manuals, this has ceased to be a mandatory rule of successful surgery. Despite the significant influence of the intersection of this vessel on intraoperative hemodynamics, surgical tactics with its later intersection have their own justifications and do not lead to a deterioration in treatment results. The standard volume of surgical intervention for pheochromocytomas is total adrenalectomy, however, in the presence of hereditary syndromes, such as multiple endocrine neoplasia type 2 syndrome, neurofibomatosis type 1, von Hippel-Lindau syndrome, it is possible to perform cortical-sparing adrenalectomy.

本文综述了肾上腺嗜铬细胞瘤患者的术前准备、手术治疗和随访的现代方面。术前准备的主要组成部分是使用α受体阻滞剂。是否需要给所有患者开处方,尤其是对没有严重高血压的患者,争议越来越大。越来越多的出版物证明了不使用α -受体阻滞剂治疗的积极结果,提倡个体化治疗方法,并根据某些适应症使用药物。微创内窥镜肾上腺切除术技术在外科治疗中已得到广泛应用。它们以腹腔镜和后腹膜镜技术为代表,包括使用它们的单孔修改。在过去,中心静脉最早可能的交叉点被认为是嗜铬细胞瘤肾上腺切除术最重要的方面,目前,由于手术技术和麻醉手册的发展,这已不再是手术成功的强制性规则。尽管该血管的交点对术中血流动力学有重要影响,但其交点较晚的手术策略有其自身的理由,并不会导致治疗结果的恶化。嗜铬细胞瘤手术干预的标准量是全肾上腺切除术,然而,在存在遗传性综合征的情况下,如多发性内分泌瘤变2型综合征、1型神经纤维瘤病、von Hippel-Lindau综合征,可以进行保留皮质的肾上腺切除术。
{"title":"[Surgical treatment of pheochromocytoma].","authors":"Sh Sh Shikhmagomedov, D V Rebrova, L M Krasnov, E A Fedorov, I K Chinchuk, R A Chernikov, V F Rusakov, I V Slepstov, E A Zgoda","doi":"10.14341/probl13283","DOIUrl":"10.14341/probl13283","url":null,"abstract":"<p><p>This review article contains a summary of modern aspects of preoperative preparation, surgical treatment, and follow-up of patients with adrenal pheochromocytomas. The main component of preoperative preparation is the use of alpha-blockers. The need to prescribe them to all patients is increasingly disputed, especially for patients without severe hypertension. An increasing number of publications demonstrate positive results of treatment without the use of alpha-blockers, advocating an individual approach and the use of the drug according to certain indications. Minimally invasive endoscopic techniques of adrenalectomy have become widespread in surgical treatment. They are represented by laparoscopic and retroperitonescopic technic, including using their single-port modifications. The earliest possible intersection of the central vein in the past was considered the most important aspect of adrenalectomy for pheochromocytoma, currently, due to the development of surgical techniques and anesthesiological manuals, this has ceased to be a mandatory rule of successful surgery. Despite the significant influence of the intersection of this vessel on intraoperative hemodynamics, surgical tactics with its later intersection have their own justifications and do not lead to a deterioration in treatment results. The standard volume of surgical intervention for pheochromocytomas is total adrenalectomy, however, in the presence of hereditary syndromes, such as multiple endocrine neoplasia type 2 syndrome, neurofibomatosis type 1, von Hippel-Lindau syndrome, it is possible to perform cortical-sparing adrenalectomy.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"69 5","pages":"39-44"},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Problemy endokrinologii
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1